Bordetella pertussis causes whooping cough, a severe respiratory tract infection in infants and children, and also infects adults. Studies in murine models have shown that innate immune mechanisms involving dendritic cells, macrophages, neutrophils, natural killer cells, and antimicrobial peptides help to control the infection, while complete bacterial clearance requires cellular immunity mediated by T-helper type 1 (Th1) and Th17 cells. Whole cell pertussis vaccines (wP) are effective, but reactogenic, and have been replaced in most developed countries by acellular pertussis vaccines (aP). However, the incidence of pertussis is still high in many vaccinated populations; this may reflect sub-optimal, waning, or escape from immunity induced by current aP. Protective immunity generated by wP appears to be mediated largely by Th1 cells, whereas less efficacious alum-adjuvanted aP induce strong antibody Th2 and Th17 responses. New generation aP that induce Th1 rather than Th2 responses are required to improve vaccine efficacy and prevent further spread of B. pertussis .
INTRODUCTION
Bordetella pertussis , the causative agent of pertussis or whooping cough is a Gram-negative, aerobic coccobacillus of the genus Bordetella that also includes Bordetella parapertussis , which can infect humans and Bordetella bronchiseptica , which mainly infects animals such as dogs, cats, and pigs . B. pertussis still accounts for significant morbidity and mortality in children worldwide. 1, 2 The World Health Organization estimated that there were 16 million cases of pertussis worldwide in 2008 and that 195,000 children died from the disease, mostly in developing countries. 1 Whole-cell pertussis vaccines (wP) were introduced in the 1950s, but because of their reactogenicity, were replaced in most developed countries over 10 years ago by safer acellular pertussis vaccines (aP), comprising two or more protective antigens. Although an extensive course of immunization with aP provides a good level of protection against severe pertussis in children, the incidence of pertussis has increased in many developed countries, particularly in adolescents and adults. Furthermore, 10 infant deaths from over 7,200 cases of pertussis were reported in California in 2010, which was the highest number of cases reported since 1947, surpassing a recent peak of 3,182 cases in 2005. 3 The epidemic was not confined to California, with similar reports from Michigan, Ohio, and Oklahoma and in other countries, including Australia and Ireland. 4 -6 This resurgence of pertussis may, in part, reflect improved detection methods, but may also be associated with escape from immunity owing to antigen variation or poor or short-lived adaptive immunity induced by the aP when compared with the wP that they replaced.
Although no single correlate of immunity has emerged, considerable progress has been made in our understanding of the complex mechanisms of protective immunity to B. pertussis. Studies in humans have been complemented by more revealing experiments in murine respiratory challenge models. Although not perfect for replicating certain aspects of the human disease, notably the cough, the mouse models have provided very useful tools to dissect the role performed by different arms of the innate and adaptive immune response during the bacterial clearance and have highlighted potential approaches to improve vaccine efficacy in humans. One issue that has complicated our understanding of immunity to B. pertussis and the development of effective subunit or acellular vaccines is that B. pertussis produces a number of toxins, including pertussis toxin (PT), tracheal cytotoxin (TCT), adenylate cyclase toxin (ACT), heat-labile toxin, and endotoxin or lipopolysaccharide (LPS), and a range of other critical receptor-binding virulence factors, including filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae, all of which are known to contribute to pathogenesis and many of which are antigenic targets for antibodies and T cells. In addition, many of these toxins and virulence factors, Immunity to the respiratory pathogen Bordetella pertussis REVIEW as well as mediating adherence to ciliated epithelial cells, macrophages, and neutrophils, also promote bacterial survival in the respiratory tract by subverting immune responses of the host. Furthermore, as well as replicating extracellularly on respiratory epithelial cells, B. pertussis can also be taken up and survive in macrophages, suggesting that cell-mediated as well as humoral immunity are required for clearance of the bacteria from the respiratory tract.
Studies on cellular immunity to B. pertussis have shown that recovery from whooping cough in children is associated with the induction of interferon (IFN)--secreting T helper type 1 (Th1) cells. 7, 8 Complementary studies in mice have shown that IFN-is required for the control of B. pertussis infection in the respiratory tract; mice lacking this cytokine or its receptor develop disseminating and lethal infection. 9, 10 Furthermore, experiments involving cell depletion or adoptive transfer have provided convincing evidence of a role for Th1 cells in clearance of a primary infection or following immunization with wP. 9,11 -13 By contrast, immunization of mice with aP induces Th2-type responses, which promote humoral immunity, but do not appear to be as effective as Th1 cells in clearance of B. pertussis from the respiratory tract. Clinical studies concur with these findings and have demonstrated selective induction of Th1 cells in children following immunization with wP but strong antibody and Th2 dominated responses following immunization with aP. 14, 15 Thus, the failure of alum-adjuvanted aP to induce Th1 responses, and hence IFN-secretion, may be one explanation for the increasing incidence of pertussis in populations using aP.
LOCAL IMMUNITY TO B. PERTUSSIS IN THE RESPIRATORY TRACT
B. pertussis binds to the cilia of the trachea, bronchi, and bronchioles and intracellular bacteria have been detected in the ciliated epithelial cells and macrophages from the lungs of infected infants / children and mice. 16 -19 Resident and infiltrating macrophages and immature dendritic cells (DCs) are the first cells of the innate immune system to sense and respond to B. pertussis infection ( Figure 1 ). Studies in the murine respiratory challenge model have shown that infection of naive mice with B. pertussis is accompanied by an inflammatory infiltrate in the lungs, with an influx of DCs, macrophages, neutrophils, and lymphocytes. 20 An initial infiltrate of DCs and macrophages is followed by an influx of neutrophils, then natural killer (NK) cells, and finally T cells, predominantly though not exclusively CD4 + T cells. 12, 13, 20 Secretory immunoglobulin A (IgA) and IgG (which transudates from the serum) is also detected in the lungs of mice; however, serum IgG is only detectable when the bacteria are almost cleared from the respiratory tract. 11 These findings provide indirect evidence that innate cells, including macrophages and neutrophils, activated by cytokines secreted by NK cells and CD4 + T cells, help to clear a primary infection with B. pertussis . Although B. pertussis -specific antibodies and T cells confer adaptive immunity induced by previous infection or vaccination, there is rapid cell recruitment to the lungs following re-challenge of immune mice, suggesting that infiltrating cells may also contribute to protection (at least in mice) in the immune host.
INNATE IMMUNITY TO B. PERTUSSIS Macrophages
B. pertussis have been found in pulmonary alveolar macrophages from infants and children with confirmed B. pertussis pneumonia 18 and in alveolar macrophages of HIV-infected children. 21 Animal models of B. pertussis infection and in vitro studies using human monocytes have revealed that B. pertussis can enter, survive, and persist in macrophages, 16, 19, 22, 23 suggesting that these cells may provide an intracellular niche to extend infection, and increase the opportunity to spread to new hosts. Shortly after phagocytosis, a high proportion of ingested bacteria are destroyed within acidic compartments, but a proportion of the bacteria can evade destruction and can replicate in macrophages by residing in the non-acidic compartments. 24 As well as providing an intracellular niche for survival, macrophages have also been shown to contribute to protective immunity; depletion of resident airway macrophages enhanced infection by B. pertussis. 16 The killing of B. pertussis by macrophages is enhanced by IFN- 25 and interleukin (IL)-17. 26 Nitric oxide (NO) production by macrophages is induced by IFN-, but not by IL-17, 26 which is consistent with the demonstration that macrophages utilize both NO-dependent and independent mechanisms to kill B. pertussis. 25 Collectively these findings suggest that the macrophages can harbor B. pertussis intracellularly and as macrophages can be activated to kill intracellular B. pertussis by T-cell derived cytokines, such as IFN- 25 ( Figure 2 ). Stimulation of DC with ACT promotes activation of caspase-1 and the NOD-like receptor (NLR) family, pyrin domain-containing 3 (NLRP3) inflammasome required for processing of the pro-IL-1 to its mature form and IL-1 , together with IL-23, promote the induction of B. pertussisspecific Th17 cells. 29 Similarly, infection of monocyte-derived human DC with B. pertussis induces IL-1 and IL-23 required for expansion of human Th17 cells. 30 The B. pertussis virulence factors ACT and FHA promote antiinflammatory responses, including IL-10 production by DC, leading to the generation of IL-10-producing regulatory T (Treg) cells. 27, 31 Furthermore, although LPS promotes proinflammatory responses, it also stimulates IL-10 production from DC, 27 which can drive the induction of Treg cells. These Treg cells have a putative protective role as the absence of IL-10-secreting T cells resulted in increased mortality from overwhelming inflammation in the lungs caused by B. pertussis infection. 27, 32 Neutrophils B. pertussis is taken up and can survive within subcellular structures in neutrophils that undergo lysosomal maturation. 33 Unlike macrophages, however, neutrophils are unlikely intracellular reservoirs for B. pertussis due to their short half-life, but they may have a role in killing phagocytosed bacteria. Neutrophils infiltrate the lungs of mice around 5 days after respiratory challenge with B. pertussis and peak around day 10 -14. 20, 34 Innate IL-6 is required for macrophage inflammatory protein 2 production and associated neutrophil recruitment as well as induction of Th1 and Th17 responses to B. pertussis . 35 PT was shown to modulate the early immune response to B. pertussis by delaying the early infiltration of neutrophils. 36 Similarly, ACT can inhibit neutrophil function by decreasing phagocytosis, superoxide generation, and inhibiting chemotaxis. 37 However, this does not appear to impact on protective immunity to B. pertussis ; although B. bronchiseptica infection of neutrophildeficient mice has a lethal outcome, neutrophils do not appear to have a critical role in clearing B. pertussis infection in naive mice. 36, 38 Nevertheless, neutrophils appear to be important in controlling infection in immune mice, possibly through antibody-mediated uptake and intracellular killing. 36 
NK cells
NK cells have a well-documented role in killing virally-infected cells, but also function in immunity to certain bacterial infections, including B. pertussis . Following B. pertussis infection of mice, NK cells provide the initial source of IFN , which is essential for containing the bacteria within the respiratory tract, 13 and promoting Th1 responses that mediate bacterial clearance. 9, 10 Evidence of a protective role for NK cells was provided by the demonstration that B. pertussis infection of T-cell -deficient mice, though persistent, is confined to the lungs, 11 whereas depletion of NK cells resulted in dissemination of the bacteria to the liver. 13 Depletion of NK cells also resulted in a reduced Th1 and an elevated Th2 response, highlighting a role for NK cells in regulating the development of T-cell responses during infection. 13 
Antimicrobial peptides
A range of host defence proteins are secreted by the airway epithelium and innate immune cells, either constitutively or in response to bacterial infection. 39 These include large proteins, such as lysozyme, lactoferrin, and secretory leukoproteinase inhibitor, and also the smaller antimicrobial peptides (AMPs), such as cathelicidin (LL-37) and the defensins. Variable susceptibility of B. pertussis to AMPs in vitro was demonstrated by radial diffusion assay, with AMPs of the cecropin family found to be the most effective, whereas -defensin and magainin AMPs were less potent. 40 However, later studies revealed that -defensins have strong antimicrobial activity against Bordetella species, such as canine -defensin CBD103 and porcine -defensin-1 (pBD-1), which is a homologue of human -defensin-2. 41, 42 Expression of pBD-1 in the upper respiratory tract of piglets ( > 4 weeks of age) correlated with resistance to respiratory infection by B. pertussis , whereas newborn piglets, which lack pBD-1 expression, are susceptible to infection but are protected following in vivo treatment with recombinant pBD-1. 41 By contrast, B. parapertussis is resistant to killing by pBD-1 in vitro , and consequently B. parapertussis challenge in the same porcine model resulted in more severe disease. 43 Taken together, these studies suggest that -defensin AMPs are selectively protective and promote resistance to B. pertussis infection. As an evasion strategy, Bordetella species can inhibit nuclear factor B activation through the type III secretion system (TTSS), thus blocking the expression of defensins, such as tracheal AMP, and promoting REVIEW survival and colonisation. 44 The induction of -defensin-2 can also be promoted by IL-17 in primary human airway epithelial cells, 45 and although this is a distinct possibility with respect to the Th17 response to B. pertussis infection, to our knowledge it has yet to be described in the literature.
Complement
The Bordetella resistance to killing A (BrkA) protein confers B. pertussis with a degree of resistance to classical complementdependent killing. 38, 46 BrkA-dependent resistance occurs through the inhibition of neutrophil-mediated phagocytosis by interfering with the deposition of complement components onto the bacterial surface. 47 However, susceptibility to complement remains highly variable. Although a mutant strain lacking BrkA was efficiently killed by sera from individuals with previous exposure to B. pertussis , partial killing of the wild-type strain was also observed and correlated with the presence of complement-fixing IgG3 antibodies. 48 Furthermore, the specific growth phase of the bacteria, but not differential antigenic expression, has a role in determining susceptibility to complement. 49, 50 Expression of O antigen, for example, does not seem to be essential for resistance to serum in B. pertussis , unlike in other Bordetella strains. 50, 51 Inhibition of the classical complement pathway by B. pertussis is also achieved through other mechanisms, such as the recruitment of C1 esterase inhibitor (C1INH) and C4b-binding protein (C4BP), which interfere with the function of C1 and C4b, respectively. 52, 53 Finally, B. pertussis does not seem to be susceptible to the alternative or mannose-binding lectin pathways, as factor-B-depleted serum retained the ability to kill B. pertussis , unlike serum depleted of antibody. 54 Indeed, clinical isolates of B. pertussis bind the alternative pathway inhibitor factor H in human serum, which retains its activity and leads to cleavage of C3b and protection from the alternative complement pathway. 55 
HUMORAL IMMUNITY
Infection of mice and humans with B. pertussis induces IgG and IgA; secretory IgA is detectable in mucosal secretions before detection of IgG in the serum, 11 suggesting that it may be important in the control of B. pertussis infection. 56 B. pertussisspecific IgG and IgA can also be acquired by human newborns via colostrums and placental transfer, and there is some evidence that these can be protective. 57 Although parentally delivered pertussis vaccines confer protection, they do not induce secretory IgA, although it is possible that rapid induction of IgA after challenge may contribute to bacterial clearance. By contrast, oral or nasally delivered pertussis antigens formulated with mucosal adjuvants do induce IgA in mice, but do not confer higher levels of protection than the equivalent parenterally delivered vaccines (Reviewed in Mills 58 ). It is possible that the nasally delivered attenuated B. pertusis vaccine BPZE1, which is highly protective in mice, 59 may have the advantage of inducing local as well as circulating IgG.
Antibody in humans
Passive immunization with antisera against B. pertussis has been shown to reduce the severity of disease in infected individuals, providing direct evidence of the protective role for antibodies in humans. 60 Furthermore, the results of phase III clinical trials of pertussis vaccine carried out in the 1990s reported that aP that included PT and FHA, with or without PRN and fimbrae, generated relatively high levels of antibodies against the immunizing antigens. 61 -65 However, these studies did not provide definitive evidence of a role for antibodies in protection against B. pertussis . Indeed, some of the vaccines with rather low efficacy also elicited relatively strong antibody responses as detected by enzyme-linked immunosorbent assay. This anomaly may reflect an overdependence on enzyme-linked immunosorbent assay for antibody detection; antibody assays with increased functional relevance have been developed and may prove more useful. Furthermore, local antibodies (IgA and IgG) in the lung may be more relevant than those in the circulation. Finally, anti-B. pertussis IgG concentrations in the serum give little information on the induction of immunological memory. Nevertheless, reports from household-exposure studies showed that the incidence of severe pertussis was lower in individuals with high serum antibody levels against PT and PRN. 66, 67 Furthermore, a study with a mono-component aP demonstrated that children were less likely to develop severe pertussis if they had higher levels of anti-PT antibodies. 68 However, although antibody responses decline rapidly after immunization with most aP, 66, 69 many immunized children appear to remain protected against severe disease. 70 These observations suggest that either memory B cells 71 or more persistent T-cell responses 72 may mediate longterm adaptive immunity to B. pertussis .
Antibody in mouse models
B. pertussis -specific antibody responses are slow to develop in mice after B. pertussis respiratory challenge and antibody responses are not detected at significant levels until the bacteria are almost cleared after 4 -6 weeks, 11 suggesting that antibodies do not have a major role in clearance of a primary infection with B. pertussis . By contrast, there is considerable evidence from passive and active immunization studies in murine models that antibodies are involved in vaccine-induced adaptive immunity to B. pertussis . 73 It is possible that antibodies may function by (a) neutralizing bacterial toxins, (b) inhibiting binding of extracellular bacteria to epithelial cells in the respiratory tract, or (c) enhancing bacterial uptake for destruction by macrophages and neutrophils.
Immunization of mice with PT, FHA, PRN, fimbriae, or ACT induces antibody responses and confers varying levels of protection against respiratory or intracerebral challenge. 58 However, few of these studies provided formal evidence that antibodies conferred protection and some even demonstrated protection with minimal or undetectable antibody responses. 72, 74, 75 Nevertheless, passive immunization experiments demonstrated that antibodies raised against distinct B. pertussis antigens can confer a level of protection. 73 Antibodies against PT and PRN appear to be the most protective, whereas anti-FHA antibodies have limited efficacy, which is consistent with the conclusions from clinical studies. Furthermore, the combination of antibodies against different antigens was most protective, 73 which is also consistent with clinical trials involving two-, three-or fivecomponent vaccines. 61 -65 Further evidence of a role for antibody in vaccine-induced immunity to B. pertussis in mice was provided by the demonstration that immunization with aP or wP failed to confer protective immunity in Ig-defective (Ig − / − ) mice. 73 Naive Ig − / − mice also failed to clear B. pertussis and developed a chronic infection. 73 However, Ig − / − mice lack mature B cells and fail to generate an effective T-cell response to B. pertussis . Intranasal immunization of Ig − / − mice with inactivated B. pertussis resulted in partial protection, which was restored to full protection after transfer of B. pertussis -immune B cells. 74 Therefore, B cells may protect against B. pertussis independently of antibody production, possibly through an organogenic role in mucosal immunity, 76 or in antigen presentation to T cells.
CELL-MEDIATED IMMUNITY
Although the overwhelming focus of most studies on defining correlates of immunity to B. pertussis have focused on serum antibody responses, there is growing evidence that cellular immunity is required for effective clearance of a primary infection with B. pertussis from the respiratory tract and for immunity induced with wP. The discovery of Th1 and Th2 cells over a quarter of a century ago and the factors that promote their differentiation, notably IL-12 and IL-4 respectively, have provide a useful framework for understanding the role of humoral and cellular immunity to infection, with Th1 cells primarily involved in immunity to intracellular pathogens and Th2 to extracellular pathogens. 77 Studies in immunized mice and humans have demonstrated that wP and aP induce distinct Th1 and Th2 subtypes, respectively. 14, 15 The more recent discovery of Treg cells, which prevent autoimmunity and immunopathology during infection, 78 and IL-17-secreting Th17 cells, which are pathogenic in many inflammatory diseases but also promote neutrophil recruitment in immunity to fungi and extracellular bacteria, 79 has added an extra layer of complexity to our understating of the role of CD4 + T cells in immunity to infection. In addition to Th1 cells, it appears that Treg and Th17 cells are induced by infection with B. pertussis and data are emerging that these cells may also have critical and distinct roles in the pathogenesis of B. pertussis infection.
REVIEW

T cells in humans
Infection of children with B. pertussis results in the priming of CD4 + T cells specific for the B. pertussis antigens PT, FHA, and PRN. 7, 80 Furthermore, T cells from the peripheral blood of infants with whooping cough or recovering from disease were found to secrete IFN-and IL-2, but little or no IL-4 or IL-5. 7 These results have been confirmed by other studies, 8, 81 and suggest that B. pertussis infection primes Th1 but not Th2 cells in children. Furthermore, T-cell clones specific for PT, FHA, or PRN derived from an adult donor who had suffered from whooping cough were shown to have a cytokine profile characteristic of Th1 cells. 82 T-cell proliferative responses to PT, FHA, or PRN were shown to inversely correlate with clinical pertussis. 83 B. pertussis -specific Th1 responses have also been detected in a proportion of " naive " children with no history of whooping cough, 7 and in healthy adults with no record of vaccination, or history of pertussis. 84 It is possible that natural exposure and the development of sub-clinical pertussis may help to maintain long-term immunity in previously infected or immunized individuals. Taken together, the data are consistent with a role for cellular responses mediated by Th1 cells in natural immunity to B. pertussis in humans. However, recent studies in humans have suggested that Th17 cells are also induced in response to B. pertussis , 30 and studies in mice have demonstrated that these cells may also have a role in protective immunity. 26, 85 However, IL-23-driven Th17 cells are pathogenic in murine autoimmune diseases and IL17R or IL23R have been identified as possible susceptibility genes in certain autoimmune diseases in humans. 86 Furthermore, polymorphisms in IL23R are associated with protection against pulmonary hypertension in systemic sclerosis. 87 As leukocytosis and pulmonary hypertension is common in fatal cases of pertussis in young infants, 18 it is possible Th17 cells may also contribute to pulmonary pathology during B. pertussis infection.
Immunization of children with wP, like natural infection, induces B. pertussis -specific CD4 + T cells that secrete IFN-. 14, 15 Although one report concluded that aP also selectively induced Th1 cells, 88 studies from several independent laboratories demonstrated that primary immunization with aP generated T cells with a Th2 or mixed Th1 / Th2 cytokine profile. 14, 15, 89 In addition, administration of a fourth or fifth booster immunization significantly enhanced Th2 responses and IgE production. 90 Furthermore, the Th1 profile induced with wP was broadened to a mixed Th1 / Th2 profile after boosting with aP. 14 An examination of T-cell responses in children at extended intervals after immunization demonstrated persistence of the T-cell responses in a high proportion of individuals. 14,91 However, injectionsite reactions, including redness and limb swelling, have been reported in children after a fifth dose of aP. 92 As Th2 responses are particularly pronounced after a booster vaccination with aP, it is possible that the local reactions can be attributed to hypersensitivity mediated by Th2 cells.
Effector T cells in murine models
T cells are recruited to the lungs early after infection of mice with B. pertussis. 20 TCR − / − mice have a lower B. pertussis bacterial load early in infection but increased lung pathology compared with wild-type mice; this study concluded that T cells have a role in orchestrating early innate cell traffic to the respiratory tract. 93 The development of an adaptive immune response following primary B. pertussis infection is relatively slow, with CD4 + T-cell responses detected in the lungs after about 3 weeks post infection, followed by detection in the draining lymph nodes and spleen. 11, 20 Antigen-specific CD4 + T cells from infected or convalescent mice secrete IFN-and / or IL-17, suggesting that Th1 and Th17 cells are induced by infection with B. pertussis. 11, 29 Th1 cells differentiate from naive T cells in response to the inflammatory cytokine IL-12 secreted by innate immune cells in response to various B. pertussis virulence factors. 94 B. pertussis -infected IFN-− / − mice have a significantly impaired ability to clear the bacteria, 10 and IFN-R − / − mice can develop a lethal disseminated infection. 9 IFN-produced by Th1 cells activates NO production by macrophages, which help to eliminate the bacteria. 25, 95, 96 Little or no Th2 cells are induced following primary infection of mice with B. pertussis mice. 34 Furthermore, IL-4 − / − mice clear B. pertussis infection at the same rate as wild-type mice. 34 Interestingly, although IFN-R − / − mice lack Th1 responses, and Th2 cells do not develop in these mice, they can still clear the bacteria if they survive the initial infection, 9 probably through the function of Th17 cells. These IL-17-producing CD4 + cells are induced during infection, 29, 30, 97 driven by innate IL-1 and IL-23, and are critical for successful clearance of B. pertussis 29, 35 via the recruitment of neutrophils and the activation of both macrophage-and neutrophil-mediated killing of B. pertussis. 26, 98 The induction of effective adaptive immunity against B. pertussis therefore requires both Th1 and Th17 cells.
The earliest studies on cellular immunity generated by immunization of mice showed that wP induced polarized Th1 responses, whereas aP primarily induced Th2 cells 99, 100 ( Figure 3 ). Although aP do provide protection, the rate of clearance of B. pertussis is slower in aP-compared with wPimmunized mice and this appears to reflect the failure of aP to induce Th1 cells. 99, 101, 102 Originally, the induction of Th2 cells and high levels of antibodies was thought to be the sole mechanism of aP-induced protection. 100 However, IL-4 − / − mice, which do not develop Th2 cells, are still protected by vaccination with aP (Ross and Mills, unpublished). Transfer of high-titre antibodies generated by infection or vaccination can passively transfer immunity to naive mice, 73 demonstrating a protective role for high levels of circulating antibodies. 74 However, recent results from this laboratory have identified a critical role for Th17 cells in aP-induced protection. 103 We have shown that IL-1 induced by vaccination with aP promotes IL-17 production from Th17 cells, which increases neutrophil recruitment and the activation of bacterial killing (Ross and Mills, unpublished) . We have also demonstrated that wP induces Ag-specific Th17 cells in immunized mice 26 and found that these cells work in combination with Th1 cells to mediate bacterial clearance. The mechanism appears to involve the recruitment and activation of macrophages and neutrophils, which kill B. pertussis 25, 26 and reduce the bacterial burden in the respiratory tract.
REVIEW
Treg cells
B. pertussis , like many other pathogens that cause persistent infections, has evolved mechanisms to subvert host protective immune responses and prolong their survival in the host and these include the induction of Treg cells. 104, 105 The B. pertussis virulence factors FHA and ACT promote IL-10 secretion and inhibit IL-12p70 production and maturation of DC and macrophages and thereby promote the induction of Treg cells. 31, 106, 107 Although protective Th1 and Th17 responses can be detected both locally and systemically during infection, IL-10-secreting Tr1-type cells are also detectable at the site of infection and are induced simultaneously with Th1 cells. 31 Tr1 cells secrete high levels of IL-10, with low levels of IL-5 and IFN-and no IL-4 and directly suppress inflammatory Th1 responses ( Figures 2  and 4 ). More recently, it has been shown that there are a high proportion of CD25 − Foxp3 + Treg cell in the lungs of B. pertussis -infected mice and these cells work with IL-10-secreting Treg cells to subvert bacterial clearance by modulating Th1 responses. 32 In addition to facilitating persistence of the bacteria, these regulatory responses may be of benefit to the host by limiting immune-mediated pathology. 26 
B. PERTUSSIS VIRULENCE FACTORS -PROTECTIVE ANTIGENS AND IMMUNOMODULATORY MOLECULES
B. pertussis causes a persistent respiratory tract infection, lasting many weeks or months in human infants and is often associated with secondary infections and pneumonia. Immunocompetent adult mice do not clear the infection until 5 -7 weeks post aerosol challenge with B. pertussis . Furthermore, B. pertussisspecific adaptive immune responses are slow to develop during the course of infection in naive mice 20 ( Figure 1 ). This is a reflection of the fact that B. pertussis has evolved strategies to survive and multiply within several different intracellular and extracellular environments and a variety of strategies to subvert immune responses, including the induction of immunosuppressive cytokines by innate cells 107 -110 and the generation of Treg cells 32, 105 ( Figure 5 ). The number and nature of virulence factors required to effect those strategies, and the regulatory 
REVIEW
systems that control virulence gene expression are the result of co-evolution between the bacteria and its host. 111 
FHA
FHA is the major B. pertussis adhesin expressed at the bacterial cell surface and is also secreted into the extracellular milieu. It contains several domains that promote bacterial adherence to ciliated respiratory epithelial cells, including RGD (ArgGly-Asp), carbohydrate-recognition, and heparin-binding domains. 112, 113 FHA-mediated adherence to the respiratory epithelium is enhanced in the presence of ACT 114 and cholesterol-containing lipid rafts, 115 and is associated with increased intracellular adhesion molecule 1 expression. 116 FHA also promotes phagocytosis of B. pertussis by macrophages and polymorphonuclear leukocytes, an effect that was inhibited in vitro by anti-FHA antibodies from B. pertussis-infected children. 117 FHA initiates phagocytosis by binding and activating the leukocyte integrin complement receptor 3 on macrophages and other cells, 118 following which toxin-mediated suppression of intracellular killing promotes bacterial survival. 23 Antibodies to FHA have a protective role against B. pertussis infection in mice, although studies in mice and humans suggest that it is not a key protective antigen. 66, 73 In addition to its role in bacterial adherence and phagocytosis, secreted FHA also has important immunomodulatory functions, 113 including the induction of IL-6 and IL-10 and suppressing IL-12 production by macrophages and DCs. 31, 106 This leads to the generation of IL-10-producing Treg cells that 
REVIEW
suppress IFN-production and thus inhibit the generation and function of Th1 cells. 31, 106 Furthermore, monocyte-derived IL-10 has recently been shown to inhibit FHA-induced IFNsecretion by mononuclear cells from vaccinated infants, suggesting that FHA has an immunosuppressive function during infection of humans with B. pertussis . 119 It has also been reported that B. pertussis FHA can interfere with nuclear factor B signalling leading to suppressed immune responses, which was attributed to inhibition of proteasome activity. 120 Finally, a recent study of the genome-wide transcriptional response of human peripheral blood mononuclear cells to B. pertussis FHA showed immunomodulatory effects on several members of the type I IFN and the ISGylation pathways. 121
PT
PT is a secreted virulence factor and a key protective antigen of B. pertussis ; detoxified PT is a component of all aP vaccines licensed to date. PT consists of an A monomer with catalytic adenosine diphosphate (ADP) ribosyltransferase activity and a B oligomer that binds surface glycoproteins on a variety of host cells. 122 -124 PT is known to promote several systemic effects, such as lymphocytosis and histamine sensitisation, and also has adjuvant activity, promoting T-cell responses to bystander antigens. 125 Following infection, PT initially facilitates FHA-mediated adhesion of B. pertussis to macrophages by mimicking eukaryotic P-and E-selectins and thereby upregulating complement receptor 3 (CR3; CD11b / CD18) expression. The different subunits of PT contribute to the immunomodulatory effects on host cells, and can either promote or suppress host immune responses. The A subunit inactivates cytoplasmic G proteins, which inhibits several chemokine signalling pathways and leads to impaired macrophage, neutrophil, and lymphocyte chemotaxis. 126 PT has been shown to inhibit phagocytosis by antigen-presenting cell, antigen processing and presentation, and trafficking of antigen-presenting cells to lymph nodes. 127, 128 In addition, the B oligomer of PT activates several T-cell receptor -associated signalling molecules in lymphocytes, including Zap70 and protein kinase C, 129 which can subsequently promote immunosuppression via cross-desensitisation of the T-cell receptor and the chemokine receptor CXCR4. 130 Studies of mice infected with a mutant B. pertussis strain lacking the ptx gene, 98, 131, 132 or treated with recombinant PT, 133 collectively found that PT inhibited chemokine expression, neutrophil recruitment to the lungs, serum antibody levels, and bacterial clearance. Indeed, these immunosuppressive effects of PT can leave mice more susceptible to subsequent infection with influenza virus. 134 However, other studies have shown that PT can enhance CD80 / CD86 co-stimulatory molecules, 
ACT
ACT is a post-translationally acylated bifunctional toxin that preferentially targets cells of the innate immune system by binding to the complement receptor 3 complex on the cell surface, 148 but can also intoxicate complement receptor 3 -negative cells. 149 ACT inhibits the anti-bacterial functions of innate cells by inducing apoptosis and cell cycle arrest and inhibiting phagocytosis, chemotaxis, and superoxide generation. 150 -153 ACT also modulates antigen-presenting cell function and the induction of T-cell responses. 107, 153, 154 ACT is activated by calmodulin binding and catalyses the formation of supraphysiological levels of cAMP, which inhibits the anti-bacterial function of macrophages and suppresses the secretion of the inflammatory cytokines IL-12p70 and TNF-, and promotes secretion of IL-10. 107, 108 Together with IL-10 induced by FHA 31 and TTSS, 85, 109, 110 this promotes the development of antigen-specific Tr1-type Treg cells, which subvert the host immune response and delay the clearance of the bacteria. 107, 108, 155 However, ACT also promotes inflammatory responses and acts synergistically with TLR2 and TLR4 to increase COX-2 expression. 156 Furthermore, the hydrophobic C-terminal domain of ACT forms pores in the target cell membrane causing K + efflux, 157 which promotes the formation and activation of the NLRP3 inflammasome complex resulting in the activation of caspase-1 and the release of bio-active IL-1 from LPS-primed DC. 29 This IL-1 is critical for host protection and clearance of B. pertussis via the induction of IL-17-producing Th17 cells and the recruitment of neutrophils to the site of infection. 29 Immunization with ACT can induce a level of protective immunity in mouse models, 158, 159 and may be a useful addition to aP, but has not yet been assessed as a vaccine antigen in humans.
LPS
The LPS molecule of B. pertussis lacks the O antigen of other bacterial LPS structures and is, therefore, more correctly referred to as lipooligosaccharide. 160 Studies with B. pertussis containing a mutated LPS (deletion of wlb locus, leaving LPS molecules consisting of lipid A and core oligosaccharide), have shown that this virulence factor is required for colonisation and survival of Bordetella in vivo . 161 Similar to LPS from other Gram-negative bacteria, LPS from Bordetella species is pyrogenic, mitogenic, toxic, and can activate pro-inflammatory cytokine production from macrophages. 162, 163 Studies with TLR4-defective mice suggested that LPS signaling mediated through TLR4 was required for the robust innate response in eliciting protective immunity against B. pertussis . 27 TLR4-defective mice had higher bacterial colonization of the lungs, increased cellular infiltrate, and increased lung pathology. 27 However, it has also been reported that immune responses triggered early in infection via TLR4 can impair colonization with B. pertussis . 163 Independent of its immunostimulatory capacity, the LPS moiety of B. pertussis is also thought to act as a shield, through steric hindrance, protecting the bacterium from neutralization by the pulmonary collectins surfactant protein A and surfactant protein D. 50, 164 LPS is present in varying concentrations in most wP and in combination with other toxins, in particular PT, it is responsible for wP reactogenicity, including systemic and neurological effects. 165 -167 However, removal of LPS can decrease the efficacy of wP. 168 It appears that LPS is required for the adjuvant effect of wP, through the induction of IL-12, required for the differentiation of naive T cell to Th1 cells 94 and IL-1 production, which promotes Th17 responses. Further evidence of a role for LPS in the protective efficacy of wP was provided by the demonstration that wP failed to generate protective immunity in TLR4-defective mice; 26 antigen-specific IL-17 and IFN-production was significantly lower in wP-immunized TLR4-defective mice. 26 Furthermore, the protective efficacy of wP was reduced in IFN-R-defective mice 73 or by neutralization of IL-17, 26 suggesting that LPS contributed to wP-induced immunity by promoting the induction of Th1 and Th17 cells.
TCT
TCT is a 9.2-kDa disaccharide-tetrapeptide monomer of peptidoglycan that is secreted by growing B. pertussis . 169 TCT is a muramyl peptide, a group of structurally related molecules that bind to the intracellular nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs), NOD-1 and NOD-2. NOD-1 was found to be the innate immune sensory receptor for TCT in mice, but not in humans. 170 This differential recognition was shown to be dependent on a structural preference for DAP-containing tetrapeptide muramyl peptides (M-Tetra DAP ) by murine NOD-1 and DAP-containing tripeptide muramyl peptides (M-Tri DAP ) by human NOD-1. 170 TCT also activates the immune deficiency pathway, an ancient innate defense pathway required for antimicrobial gene expression in response to Gram-negative bacteria. 171 TCT induces cytopathology in hamster tracheal ring organ cultures (loss of cilia, disruption of tight junctions, and extrusion REVIEW of ciliated cells from the respiratory surface) similar to the pathology observed during pertussis in humans. 169, 172 TCT also inhibits DNA synthesis in cultured hamster tracheal epithelial cells. 169 TCT-mediated inhibition of proliferation of these cells may reflect a secondary effect of TCT on the capacity of respiratory epithelium to regenerate the lost ciliated cell population. 169 IL-1 has been implicated in TCT-mediated toxicity; TCT stimulates IL-1 production by respiratory epithelial cells and recombinant IL-1 inhibits DNA synthesis and causes destruction of epithelial cells in hamster tracheal organ culture. 173 TCT and LPS have been found to act in synergy to induce IL-1 , inducible NOS, NO, and the inhibition of DNA synthesis by epithelial cells. 174 TCT is also toxic to human neutrophils. 175 
TTSS
The TTSS is a needle-like structure that enables invading bacteria to inject effector proteins into host cells. 176 Although the majority of Bordetella TTSS research to date has focused on B. bronchiseptica , the TTSS of B. pertussis has been shown to be functional and subvert both innate and adaptive host immune responses. 85 Mice infected with TTSS-deficient B. pertussis (harbouring a bscN mutation) had lower bacterial colonization and greater pro-inflammatory cytokine release in the lungs, and higher antigen-specific IL-17 and IFN-production than mice infected with wild-type bacteria. 85 Early work demonstrated that B. pertussis has a bsc locus containing multiple TTSS genes, 177, 178 although a posttranscriptional event prevented the secretion of TTSS proteins. 179 More recent work has shown that although B. pertussis does express a functional TSSS, not all strains express the full complement of TTSS proteins; expression of the TTSS protein Bsp22, for example, was detected in 15 of 16 clinical isolates of B. pertussis and in low-passage strains, but not in the common Tahoma I laboratory strain. 85 Two further TTSS proteins, BopD and BopN, were also detected in the low-passage strain B. pertussis 12743, but not in the Tahoma I strain, whereas BteA (also called BopC) was not detected in any of the B. pertussis strains investigated in this study. 85 The lack of expression of BteA in certain B. pertussis strains is due to an IS 481 insertion in the 5 Ј untranslated region of the gene, resulting in BteA being expressed at higher levels in B. pertussis non-vaccine-type strains than in vaccine-type strains. 180 A lack of BteA expression might explain the inability of B. pertussis 12743 to mediate cytotoxicty in vitro , 85 as B. bronchiseptica BteA protein has been shown to induce necrosis and tyrosine dephosphorylation in host cells, 181 although this is unclear as BteA-expressing strains of B. pertussis showed low cytotoxicity in a separate study. 180 Furthermore, laboratory adaptation and long-term passaging was associated with a loss of TTSS protein expression in both the laboratory and clinical B. pertussis strains, although this could be reversed when the inactivated strains were used to infect mice. 182 Taken together, these findings suggest that the TTSS expression profile of highly passaged laboratory strains may not reflect that of clinically relevant strains that infect humans, which may have serious implications for vaccine efficacy.
CONCLUSIONS AND PERSPECTIVES ON FUTURE PERTUSSIS VACCINES
Major questions that need to be addressed in the field of pertussis include, should the aP be updated to include a more relevant adjuvant or different antigenic components, and should adolescents and adults be vaccinated in an attempt to prevent the carriage and spread of B. pertussis and reduce the global incidence of this disease? Given the increasing incidence of pertussis in vaccinated populations, 1,2 strategies to raise the efficacy and longevity of the protection induced by aP to that of the original wP should be investigated taking cognisance of recent discoveries on the mechanisms of vaccine-induced immunity, especially the role of T-cell subtypes.
The lower efficacy of aP compared with wP may reflect faster waning of immunity induced by aP. It may also be caused by selection pressure and antigenic variation, which allow the circulating B. pertussis strains to escape immunity induced by the antigens in aP, as they are derived from the historic laboratory strains. 6, 183, 184 Alternatively, it may reflect the choice of adjuvant for existing aP. Currently, aP are administered with alum as the adjuvant and although having a long history of safety in humans, alum favors the induction of Th2 cells and antibodies. Recent studies in our laboratory have shown that wP or natural infection, which induce relatively high levels of protection, promote Th1 and Th17 responses, whereas aP induces Th17 and Th2 cells in mice (Ross and Mills, unpublished) . Therefore, introduction of alternative adjuvants that favor the induction of Th1 cells, 94, 185, 186 will provide better protection against B. pertussis than a vaccine formulated with alum. 103 Furthermore, as aP are known to be more efficacious when they include a higher number or antigens, 2,62 the inclusion of additional antigens from B. pertussis that are known to contribute to protective immunity, such as ACT and BrkA, 158, 159, 187 could improve the levels of protection induced by aP.
